Geoffrey Wong, MD
Vascular Surgery · South Plainfield, NJNPI 1811916745
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Boston Scientific at 59.6% of the total. 2025 is the largest year on record at $10,750, more than ten times the $1,065 reported in 2019.
Across 220 payments — averaging $100.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$13K
- Penumbra, Inc.$3K
- Silk Road Medical, Inc.$1K
- Cardiovascular Systems Inc.$859
- Inari Medical, Inc.$704
- Cook Medical LLC$450
- plus $3K from 26 others
What the payments were for
- Consulting fees$4,87522%
- Speaking & faculty fees$2,50011%
- Travel & lodging$3,69417%
- Food & beverage$10,96050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 103 | $13,129 |
| Penumbra, Inc. | 9 | $2,798 |
| Silk Road Medical, Inc. | 10 | $1,176 |
| Cardiovascular Systems Inc. | 18 | $859 |
| Inari Medical, Inc. | 11 | $704 |
| Cook Medical LLC | 14 | $450 |
| Cvrx, Inc. | 5 | $410 |
| Limflow Inc. | 3 | $360 |
| Biotissue Holdings Inc. | 3 | $318 |
| W. L. Gore & Associates, Inc. | 3 | $220 |
| Medtronic | 3 | $220 |
| Bard Peripheral Vascular, Inc. | 2 | $203 |
| Kerecis Limited | 3 | $166 |
| Shockwave Medical, Inc | 3 | $160 |
| Stryker | 1 | $155 |
| Cagent Vascular Inc | 3 | $113 |
| Surmodics, Inc. | 1 | $100 |
| Organogenesis Inc. | 5 | $98 |
| Smith+Nephew | 2 | $51 |
| Lemaitre Vascular, Inc. | 2 | $44 |
| Johnson & Johnson | 3 | $40 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $37 |
| Acist Medical Systems, Inc. | 1 | $35 |
| Convatec Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Endologix LLC | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $20 |
| Acera Surgical, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$8,206
- RUBY Coil$2,238
- ENROUTE Transcarotid Neuroprotection System$975
- ENROUTE Transcarotid Stent System$975
- ENHANCE Transcarotid Peripheral Access Kit$975
- ENROUTE 0.014 Guidewire$975
- FLOWTRIEVER CATHETER, S$491
- CT THROMBECTOMY SYSTEM KIT$491
- GENERAL ANGIOGRAPHY$469
- Kerecis Omega3 Marigen$387
- Indigo System$371
- LIMFLOW SYSTEM$348
- Barostim Neo System$269
- JETSTREAM SC$235
- Peripheral Orbital Atherectomy System$227
- GENERAL VASCULAR INTERVENTION$149
- GENERAL THROMBECTOMY$144
- GENERAL NON VASCULAR INTERVENTION$139
- GENERAL ATHERECTOMY$138
- Arterial Wolf$135
How this compares
$22,029 in reported general payments places this provider in the 80th percentile of 182 vascular surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $60,655 |
| XareltoRivaroxaban | 48 | $32,079 |
| ClopidogrelClopidogrel Bisulfate | 150 | $1,843 |
| Cilostazol | 32 | $793 |
| Gabapentin | 43 | $408 |
| Warfarin Sodium | 32 | $384 |
| Doxycycline Hyclate | 11 | $197 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $64 |
| Furosemide | 37 | $36 |
| Tramadol Hcl | 15 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $40 | $32,07948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 vascular surgery providers in New Jersey.
Other vascular surgery in South Plainfield
- Steven EliasEnglewood$509K
- Michael WildermanHackensack$383K
- David O'ConnorHackensack$272K
- Joseph LombardiPomona$266K
- William BeckermanNew Brunswick$176K
- Neil PoulsenRockaway$148K
- Massimo NapolitanoWayne$147K
- Laurel HastingsCamden$98K
- Danielle PinedaPomona$97K
- Saum RahimiNew Brunswick$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.